drugset
Drugs / mRNA-1010
last change Jun 2026 re-read 3 minutes ago

mRNA-1010

Messenger RNA (mRNA)

Developed for
influenza
Investigated by
ModernaTX, Inc.

Trials 10

today NCT06602024 · Ph 3 NCT05868382 · Ph 2 NCT05827978 · Ph 3 NCT05606965 · Ph 2 NCT05585632 · Ph 1 NCT05566639 · Ph 3 NCT05415462 · Ph 3 NCT05397223 · Ph 1 NCT05375838 · Ph 1/2 NCT04956575 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT05585632 Oct 2022 → Feb 2024 Orthocoronavirinae infectious disease, influenza, respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 1 NCT05397223 May 2022 → Feb 2026 COVID-19, cytomegalovirus infection, influenza, respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05375838 May → Dec 2022 COVID-19, influenza ModernaTX, Inc. Completed No outcome recorded
Phase 1/2 NCT04956575 Jul 2021 → Sep 2022 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT05868382 May → Dec 2023 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 2 NCT05606965 Nov 2022 → Nov 2025 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 34 trials · 2 met primary
Phase 3 NCT06602024 Sep 2024 → Aug 2025 influenza ModernaTX, Inc. Completed Met primary
Phase 3 NCT05827978 Apr 2023 → Jun 2024 influenza ModernaTX, Inc. Completed Met primary
Phase 3 NCT05566639 Sep 2022 → Jan 2024 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 3 NCT05415462 Jun 2022 → Sep 2023 influenza ModernaTX, Inc. Completed Mixed
Comparator or background therapy2 trials
Phase 1/2 NCT05827068 Comparator Mar → Nov 2023 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 1/2 NCT05333289 Comparator Apr → Nov 2022 influenza ModernaTX, Inc. Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2026-06-18 ModernaTX, Inc. Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine q4web.com ↗
2026-05-06 ModernaTX, Inc. Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 q4web.com ↗
2026-02-10 ModernaTX, Inc. Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 q4web.com ↗
2023-02-16 ModernaTX, Inc. Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate q4web.com ↗
2022-06-07 ModernaTX, Inc. Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010) q4web.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as mRNA-1010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05415462 ↗
11

NCT05585632 ↗

NCT05566639 ↗

NCT05375838 ↗

NCT05868382 ↗

NCT05397223 ↗

NCT04956575 ↗

NCT05827068 ↗

NCT05333289 ↗

NCT06602024 ↗

NCT05827978 ↗

Show 1 more source
Modality Messenger RNA (mRNA) “a quadrivalent messenger RNA (mRNA) vaccine against seasonal influenza, mRNA-1010” PMID 37336877 ↗ Jun 2023
Route Intramuscular “by intramuscular (IM) injection on Day 1.” NCT04956575 ↗